Abstract
Autism spectrum disorder (ASD) is a particularly important risk factor for challenging behaviours such as aggression, tantrums, self-injury and pica. Adults with ASD have rarely been studied with respect to these problems. This is particularly disconcerting since there are far more adults than children with ASD. In addition, because of adults’ increased physical size and longer history of these problems, treating these behaviours effectively is important.
Psychological methods, particularly applied behaviour analysis, and pharmacotherapy have been the most frequently addressed treatments for challenging behaviours associated with ASD in the research literature. In many cases, challenging behaviours have clear environmental antecedents. In these cases, behavioural interventions, such as applied behaviour analysis, should be used to reduce the behaviours. When environmental factors cannot be identified or when challenging behaviours are very severe, pharmacological treatments may be necessary in combination with behavioural interventions. Newer antipsychotics are the most researched medications for use with this population. Currently, risperidone and aripiprazole are the only medications that have US FDA approval for the treatment of behaviours associated with ASD, specifically irritability; however, they are indicated for use in children not adults. It is important not to use medications unnecessarily, due to possible side effects associated with their use.
Based on available research, some recommendations for the treatment of challenging behaviours of adults (and children) with ASD include the use of functional assessment, side-effect monitoring of medications and behavioural methods whenever possible. Additionally, future research in this area needs to focus more on adults, as most current research has used child samples.
Similar content being viewed by others
References
Matson J. Determining treatment outcomes in early intervention programs for autism spectrum disorders: a critical analysis of measurement issues in learning based interventions. Res Dev Disabil 2007; 28(2): 207–18
Levy SE, Mandell DS, Schultz CJ. Autism. Lancet 2009; 374(9701): 1627–38
Lin JD, Lin LP, Wu JL. Administrative prevalence of autism spectrum disorders based on national disability registers in Taiwan. J Autism Dev Disord 2009; 3(1): 269–74
Marriage S, Wolverton A, Marriage K. Autism spectrum disorders grown up: a chart review of adult functioning. J Can Acad Child Adolesc Psychiatry 2009; 18(4): 322–8
Newschaffer CJ, Falb MD, Gurney JG. National autism prevalence trends from United States special education data. Pediatrics 2005; 115(3): e227–81
Matson JL, LoVullo SV. Trends and topics in autism spectrum disorders research. Res Autism Spectr Disord 2009; 3(1): 252–7
Emerson E, Bromley J. The form and function of challenging behaviors. J Intellect Disabil Res 1995; 39(5): 388–98
McClean B, Grey I. Modifying challenging behavior and planning positive supports. In: Carr A, O’Reilly G, Noonan Walsh P, et al., editors. The handbook of intellectual disability and clinical psychology practice. New York (NY): Routledge, 2007: 643–84
Emerson E, Kiernan C, Alborz A, et al. The prevalence of challenging behaviors: a total population study. Res Dev Disabil 2001; 22: 77–93
Ben-Itzchak E, Zachor DA. The effects of intellectual functioning and autism severity on outcome of early behavioral intervention for children with autism. Res Dev Disabil 2007; 28(3): 287–303
McClintock K, Hall S, Oliver C. Risk markers associated with challenging behaviors in people with intellectual disabilities: a meta-analytic study. J Intellect Disabil Res 2003; 47(6): 405–16
Sigafoos J. Communication development and aberrant behavior in children with developmental disabilities. Educ Train Mental Retard Develop Disabil 2000; 35(2): 168–76
Matson JL. Aggression and tantrums in children with autism: a review of behavioral treatments and maintaining variables. J Ment Health Res Intellect Disabil 2009; 2(3): 169–87
Horner RH, Carr EG, Strain PS, et al. Problem behavior interventions for young children with autism: a research synthesis. J Autism Dev Disord 2002; 32(5): 423–46
McCarthy J, Hemmings C, Kravariti E, et al. Challenging behaviors and co-morbid psychopathology in adults with intellectual disability and autism spectrum disorders. Res Dev Disabil 2010; 31(2): 362–6
Graetz JE. Autism grows up: opportunities for adults with autism. Disabil Soc 2010; 25(1): 33–47
Sturmey P, Lott JD, Laud RB, et al. Correlates of restraint use in an institutional population: a replication. J Intellectual Disabil Res 2005; 49(3): 501–6
Lee LC, Harrington RA, Chang JJ, et al. Increased risk of injury in children with developmental disabilities. Res Dev Disabil 2008; 29(3): 247–55
Herzinger CV, Campbell JM. Comparing functional assessment methodologies: a quantitative synthesis. J Autism Dev Disord 2007; 37(8): 1430–45
Sturmey P, Seiverling L, Ward-Horner J. Assessment of challenging behaviors in people with autism spectrum disorders. In: Matson JL, editor. Clinical assessment and interventions for autism spectrum disorders. New York (NY): Springer, 2009: 131–64
Matson JL, Mahan S, Hess JA, et al. Progression of challenging behaviors in children and adolescents with autism spectrum disorder as measured by the Autism Spectrum Disorders-Problem Behaviors for Children (ASD-PBC). Res Autism Spectr Disord 2010; 4(3): 400–4
Chowdhury M, Benson BA, Hillier A. Changes in restricted repetitive behaviors with age: a study of high-functioning adults with autism spectrum disorders. Res Autism Spectr Disord 2010; 4(2): 210–6
Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am 2008; 17(4): 739–52
Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48(11): 1110–9
Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89(5): 485–91
Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptom responses to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42(12): 1443–50
Matson JL. Applied behavior analysis for children with autism spectrum disorders. New York (NY): Springer, 2009
Neidert PL, Dozier CL, Iwata BA, et al. Behavior analysis in intellectual and developmental disabilities. Psychol Serv 2010; 7(2): 103–13
Weeden M, Ehrhardt K, Poling A. Conspicuous by their absence: studies comparing and combining risperidone and applied behavior analysis to reduce challenging behavior in children with autism. Res Autism Spectr Disord 2009; 3(4): 905–12
Reichow B, Volkmar FR. Social skills interventions for individuals with autism: evaluation for evidence-based practices within a best evidence synthesis framework. J Autism Dev Disord 2010; 40(2): 149–66
Koegel RL, Koegel LK, McNerney EK. Pivotal areas in intervention for autism. J Clin Child Psychol 2001; 30(1): 19–32
Virués-Ortega J. Applied behavior analytic intervention for autism in early childhood: meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes. Clin Psychol Rev 2010; 30(4): 387–99
O’Conner AB, Healy O. Long-term post-intensive behavioral intervention outcomes for five children with autism spectrum disorder. Res Autism Spectr Disord 2010; 4(4): 594–604
Campbell JM. Efficacy of behavioral interventions for reducing problem behavior in persons with autism: a quantitative synthesis of single-subject research. Res Dev Disabil 2003; 24(2): 120–38
Lang R, Didden R, Machalicek W, et al. Behavioral treatment of chronic skin-picking in individuals with developmental disabilities: a systematic review. Res Dev Disabil 2010; 31(2): 304–15
Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains in child and adolescent autism. Lancet 2003; 362(9385): 732–4
McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41(8): 921–7
West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009; 23(2): 75–89
Canitano R, Scandurra V. Psychopharmacology in autism: an update. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(1): 18–28
Aman MG, Van Bourgondien M, Wolford PL, et al. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 1995; 34(12): 1672–81
Martin A, Scahill L, Klin A, et al. High-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999; 38(7): 923–31
Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am 2008; 17(4): 787–801
Mahan S, Holloway J, Bamburg JW, et al. An examination of psychotropic medication side effects: does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID? Res Dev Disabil 2010; 31(6): 1561–9
McDougle CJ, Stigler KA, Erickson CA, et al. Pharmacology of autism. Clin Neurosci Res 2006; 6(3–4): 179–88
Deokar AM, Huff M, Omar HA. Clinical management of adolescents with autism. Pediatr Clin North Am 2008; 55(5): 1147–57
McDougle CJ, Brodkin ES, Yeung PP, et al. Risperidone in adults with autism or pervasive developmental disorders. J Child Adolesc Psychopharmacol 1995; 5(4): 273–82
McDougle CJ, Holmes JP, Carlson RC, et al. A double-blind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55(7): 633–41
Potenza MN, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Child Adolesc Psychopharmacol 1999; 19(1): 37–44
Oliver-Africano P, Murphy D, Tyrer P. Aggressive behaviors in adults with intellectual disability: defining the role of drug treatment. CNS Drugs 2009; 23(11): 903–13
Remington G, Sloman L, Konstantareas M, et al. Clomi-pramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21(4): 440–4
Cook EH, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31(4): 739–45
Iwata BA, Dorsey MF, Slifer KJ, et al. Toward a function analysis of self-injury. Anal Intervention Dev Disabil 1982; 2(1): 3–20
Matson JL, Vollmer TR. Questions about behavioral functioning [online]. Available from URL: http://www.disabilityconsultants.org [Accessed 2011 May 4]
Matson JL, Bamburg JW, Cherry KE. A validity study on the Questions About Behavioral Function (QABF) Scale: predicting treatment success for self-injury, aggression, and stereotypies. Res Dev Disabil 1999; 20(2): 163–76
Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001; 11(3): 229–38
Matson JL. Matson Evaluation of Drug Side-effects (MEDS). Baton Rouge (LA): Disability Consultants, LLC
Advocate CD, Mayville EA, Matson JL. Side effects of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Res Dev Disabil 2000; 21(1): 75–84
Holden B, Gitlesen JP. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Res Dev Disabil 2004; 25: 509–21
Handen BL, Lubetsky M. Pharmacotherapy in autism and related disorders. Sch Psychol Q 2005; 20(2): 155–71
Howlin P. Interventions and outcomes in autism. In: Singh NN, Ollendick TH, Singh AN, editors. International perspectives on child and adolescent mental health. Vol. 2. San Diego (CA): Elsevier Science, 2002: 69–99
Bradley E, Bolton P. Episodic psychiatric disorders in teenagers with learning disabilities with and without autism. Br J Psychiatry 2006; 189: 361–6
Eaves LC, Ho HH. Young adult outcome of autism spectrum disorders. J Autism Dev Disord 2008; 38(4): 739–47
King BH, Bostic JQ. An update on pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2006; 15(1): 161–75
Nevels RM, Dehon EE, Alexander K, et al. Psycho-pharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol 2010; 18(2): 184–201
Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. J Neuropsychopaharmacology 2005; 9(2): 209–13
Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006; 85(1): 254–6
Malone RP, Maislin G, Chondhury MS, et al. Risperidone treatment in children and adolescents with autism: short-and long-term safety and effectiveness. J Am Acad Child Psychiatry 2002; 41(2): 140–7
Acknowledgements
No sources of funding were used to prepare this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Matson, J.L., Sipes, M., Fodstad, J.C. et al. Issues in the Management of Challenging Behaviours of Adults with Autism Spectrum Disorder. CNS Drugs 25, 597–606 (2011). https://doi.org/10.2165/11591700-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11591700-000000000-00000